Aya Imanishi

ORCID: 0000-0001-5571-130X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Sleep and Wakefulness Research
  • Sleep and related disorders
  • Circadian rhythm and melatonin
  • Restless Legs Syndrome Research
  • Hormonal Regulation and Hypertension
  • Hormonal and reproductive studies
  • Urinary Bladder and Prostate Research
  • Sleep and Work-Related Fatigue
  • Lysosomal Storage Disorders Research
  • Genetic Neurodegenerative Diseases
  • Olfactory and Sensory Function Studies
  • Genetics and Neurodevelopmental Disorders
  • Neuroscience of respiration and sleep
  • Epilepsy research and treatment
  • Attention Deficit Hyperactivity Disorder
  • Appendicitis Diagnosis and Management
  • Pharmacological Receptor Mechanisms and Effects
  • Neurobiology of Language and Bilingualism
  • Regulation of Appetite and Obesity
  • Medicinal Plants and Neuroprotection
  • Pregnancy and Medication Impact
  • Renin-Angiotensin System Studies
  • Heart Rate Variability and Autonomic Control
  • Nitric Oxide and Endothelin Effects
  • Sexual function and dysfunction studies

Akita University
2014-2023

Sendai Kousei Hospital
2022

Akita University Hospital
2022

Individual Differences
2018

Yale University
2009

Kumamoto University
2008-2009

Prader–Willi syndrome is a congenital neurodevelopmental disorder resulting from deletion of the paternal copies genes within chromosome region 15q11‐q13. Patients with often exhibit excessive daytime sleepiness, appetite, and obesity. As case in narcolepsy, orexin (hypocretin) may be responsible for these symptoms. However, reports showing cerebrospinal fluid levels patients have been limited. The aim this study was to examine relationship between characteristic symptoms levels. We...

10.1002/ajmg.a.37542 article EN American Journal of Medical Genetics Part A 2016-01-06

Narcolepsy, a sleep disorder characterized by excessive daytime sleepiness, cataplexy and rapid eye movement abnormalities, is tightly associated with human leukocyte antigen HLA-DQB1*06:02. DQB1*06:02 common in the general population (10–30%); therefore, additional genetic factors are needed for development of narcolepsy. In present study, HLA-DQB1 664 Japanese narcoleptic subjects 3131 control was examined to determine whether alleles located trans The strongest association DQB1*06:01 (P =...

10.1093/hmg/ddu480 article EN Human Molecular Genetics 2014-09-25

Background:Recently, many studies have investigated the association between orexin A and Alzheimer's disease (AD). However, it remains to be determined whether observed changes in levels are associated with pathological underlying AD, or cognitive function. In particular, a dir ect cerebrospinal fluid (CSF) function has not been reported date. Objective:The aim of this study was identify there is direct orexinergic system AD. Methods:For study, we included 22 patients AD 25 control subjects...

10.3233/jad-190958 article EN Journal of Alzheimer s Disease 2019-11-13

Significance Narcolepsy is a chronic neurological disorder that severely affects the day-to-day life and general well-being of affected individuals. Unfortunately, treatments available to date are symptomatic therapies with an array adverse effects. Animal studies showed orexin peptide can be mechanistic therapy treat narcolepsy. However, nonpermeability brain–blood barrier limits its use in humans. Here we delivered via intrathecal route at lumbar level significantly inhibited narcoleptic...

10.1073/pnas.1722686115 article EN Proceedings of the National Academy of Sciences 2018-05-21

Abstract We examined whether symptoms of dementia are improved by olfactory nerve stimulation in Alzheimer type patients. First, a stick‐type identification ability test was performed patients with dementia, to select without dysfunctions. Then, these were randomly assigned into the intervention (n = 19) and control groups 17). To evaluate effects stimulation, we exposed group disinfecting ethanol added aroma extracts from ceder extracts. Each underwent for 8 weeks, cognitive behavioral...

10.1002/npr2.12096 article EN cc-by Neuropsychopharmacology Reports 2020-02-09

Idiopathic hypersomnia (IH) is a rare, heterogeneous sleep disorder characterized by excessive daytime sleepiness. In contrast to narcolepsy type 1, which well-defined of central disorders hypersomnolence, the etiology IH poorly understood. No susceptibility loci associated with have been clearly identified, despite tendency for familial aggregation IH. We performed variation screening prepro-orexin/hypocretin and orexin receptors genes an association study in Japanese population,...

10.1038/s41525-022-00298-w article EN cc-by npj Genomic Medicine 2022-04-12

Abstract Narcolepsy without cataplexy (NA w/o CA) (narcolepsy type 2) is a lifelong disorder characterized by excessive daytime sleepiness and rapid eye movement (REM) sleep abnormalities, but no cataplexy. In the present study, we examined human leukocyte antigen HLA-DQB1 in 160 Japanese patients with NA CA 1,418 control subjects. Frequencies of DQB1*06:02 were significantly higher compared controls (allele frequency: 16.6 vs. 7.8%, P =1.1×10 −7 , odds ratio (OR)=2.36; carrier 31.3 14.7%,...

10.1038/hgv.2015.31 article EN cc-by Human Genome Variation 2015-09-17

Myotonic dystrophy type 1 (DM1) is often characterized by excessive daytime sleepiness (EDS) and sleep-onset rapid eye movement periods caused muscleblind-like protein 2. The EDS tends to persist even after treatment of sleep apnea. We measured the cerebrospinal fluid (CSF) orexin levels in DM1 patients with compared clinical characteristics narcolepsy idiopathic hypersomnia (IHS) patients.We CSF 17 evaluated subjective using Epworth Sleepiness Scale (ESS), objective mean latency (MSL),...

10.2147/ndt.s158651 article EN cc-by-nc Neuropsychiatric Disease and Treatment 2018-02-01

Delayed sleep phase syndrome (DSPS) is a chronic dysfunction of circadian rhythm the subject that impairs functioning in social, occupational, or other spheres. High rate depression found among DSPS patients. Aripiprazole (APZ), second-generation antipsychotic, effective treatment as well schizophrenia. Recently, few case reports show effectiveness APZ treating and non-24-hour sleep-wake disorder. Therefore, we tried to treat with using APZ.Twelve subjects (including four women) aged 19-64...

10.2147/ndt.s158865 article EN cc-by-nc Neuropsychiatric Disease and Treatment 2018-05-01

Abstract Orexins/hypocretins are hypothalamic neuropeptides that promote and stabilize wakefulness by binding to the orexin receptor type-1 (OX1R) type-2 (OX2R). Disruption of orexinergic signaling results in sleep disorder narcolepsy mice, rats, dogs, humans. The antagonist suvorexant promotes blocking both OX1R OX2R. Whereas has been clinically approved for treatment insomnia because it is well tolerated experimental animals as human patients, a logical question remains why antagonists do...

10.1093/sleep/zsab043 article EN SLEEP 2021-02-20

Abstract Introduction Current hypnotic agents have next‐day residual effects. The new orexin antagonist, suvorexant, has little muscle relaxation effect on the physical and cognitive function in following morning daytime. In this study, effects of zolpidem, ramelteon placebo elderly subjects were evaluated. Methods Six men eight women aged 63–75 years received a single tablet lights then turned off. Subjects instructed to sleep from 23:00–6:00 with an interruption 4:00–4:30 for evaluations....

10.1002/npr2.12262 article EN Neuropsychopharmacology Reports 2022-06-24

Abstract The objectives of this study were to describe prevalence, incidence, and medications among patients who diagnosed with narcolepsy in Japan using a claims database. Patients identified from January 2010 December 2019 an employment-based health insurance database compiled by JMDC Inc. prevalence incidence estimated annually the overall population age sex employees their dependents aged < 75 years. Medications, examined for each quarter population, modafinil, methylphenidate,...

10.1007/s41105-022-00406-4 article EN cc-by Sleep and Biological Rhythms 2022-08-30

Sleep-tracking devices have performed well in recent studies that evaluated their use healthy adults by comparing them with the gold standard sleep assessment technique, polysomnography (PSG). These not been validated for patients psychiatric disorders. Therefore, we tested performance of three sleep-tracking against PSG disorders.In total, 52 (32 women; 48.1 ± 17.2 years, mean SD; 18 diagnosed schizophrenia, 19 depressive disorder, 3 bipolar and 12 disorder cases) were a laboratory PSG,...

10.2147/nss.s400944 article EN cc-by-nc Nature and Science of Sleep 2023-04-01

We compared the effects of two α1-adrenoceptor antagonists with different selectivity for subtypes, prazosin and naftopidil, on pelvic blood flow nitric oxide synthase (NOS) levels in spontaneously hypertensive rat (SHR). SHRs normotensive Wistar-Kyoto (WKY) rats were distributed initially four groups: group 1 received prazosin, a subtype nonselective antagonist (2 mg/kg/day); 2 selective α1A/D-adrenoceptor (10 3 cyclazosin, α1B-adrenoceptor (5 4 vehicle orally weeks. Pelvic was determined...

10.1080/10799890802176626 article EN Journal of Receptors and Signal Transduction 2008-01-01

This study investigated neighborhood walkability using Walk Score® and social participation in districts within a city among older Japanese adults.This was cross-sectional baseline data of adults from the Keeping Active across Generations Uniting Youth Aged study. In total, 2750 participants (1361 men 1389 women, mean age 72.8 ± 6.4 years) were included analysis. The questionnaire socioeconomic status, self-rated health, medical history, depressive symptoms, instrumental activities daily...

10.1111/ggi.14354 article EN Geriatrics and gerontology international/Geriatrics & gerontology international 2022-02-03

OBJECTIVE To investigate differential gene expression profiles in the bladder of spontaneously hypertensive rat (SHR), as underlying mechanisms involved hypertension‐associated dysfunction remain to be clarified. MATERIALS AND METHODS SHR and normotensive Wistar‐Kyoto (WKY) rats were distributed initially three groups: group 1 received doxazosin (30 mg/kg/day); 2 nifedipine 3 vehicle orally for 4 weeks. The alterations levels candidate genes identified by microarray analysis with potential...

10.1111/j.1464-410x.2009.08809.x article EN BJU International 2009-08-18

This study aimed to determine the burden of narcolepsy in terms direct medical costs and comorbidities compare it with respective schizophrenia, epilepsy, ulcerative colitis as controls. Patients diagnosed (at least once based on International Statistical Classification Diseases Related Health Problems, 10th Revision, code G47.4) between April 2017 March 2022 were identified health insurance claims database compiled by JMDC Inc. schizophrenia (F20), epilepsy (G40), (K51) matched Direct...

10.1016/j.sleep.2023.12.020 article EN cc-by Sleep Medicine 2023-12-26

Clozapine may cause serious side effects despite benefits in patients with schizophrenia. Thus, an accurate understanding of the side-effect profile clozapine is extremely important management its administration to Our aim was validate relationship between exposure and appendicitis onset schizophrenia.In this study, we retrospectively compared incidence cumulative schizophrenia without a history exposure. Among who visited our hospital June 2009 August 2021, extracted those treatment....

10.1186/s12888-022-04312-4 article EN cc-by BMC Psychiatry 2022-10-21

Abstract Study objectives Niemann-Pick type C (NPC) is an autosomal recessive and congenital neurological disorder characterized by the accumulation of cholesterol glycosphingolipids. Symptoms include hepatosplenomegaly, vertical supranuclear saccadic palsy, ataxia, dystonia, dementia. Some cases frequently display narcolepsy-like symptoms, including cataplexy which was reported in 26% all NPC patients more often recorded among late-infantile onset (50%) juvenile (38%) patients. In this...

10.1186/s13023-020-01531-4 article EN cc-by Orphanet Journal of Rare Diseases 2020-09-29
Coming Soon ...